CANCER:

Biliary Tract Cancer

Related cancers:

‹

Cholangiocarcinoma (142)

Gallbladder Cancer (35)

Cholangiocarcinoma (142)

Gallbladder Cancer (35)

›

FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval Precision Oncology News - 1 week
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval Precision Oncology News - 1 week
NTRK3 fusion NTRK3 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label ESMO-GI 2021 - 3 weeks
NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label ESMO-GI 2021 - 3 weeks
NTRK1 fusion NTRK1 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label ESMO-GI 2021 - 3 weeks
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ESMO-GI 2021 - 3 weeks
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	GC Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	GemOx Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	gemcitabine Sensitive: A2 - Guideline
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	ivosidenib Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	CAPOX Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	GEM-CAP Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	FP Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	CAPOX Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	XP Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	FP Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	XP Sensitive: A2 - Guideline
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Gallbladder Cancer Gallbladder Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Biliary Tract Cancer Biliary Tract Cancer	trametinib + dabrafenib Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Biliary Tract Cancer Biliary Tract Cancer	pembrolizumab Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Biliary Tract Cancer Biliary Tract Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Biliary Tract Cancer Biliary Tract Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Biliary Tract Cancer Biliary Tract Cancer	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Biliary Tract Cancer Biliary Tract Cancer	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Biliary Tract Cancer Biliary Tract Cancer	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Biliary Tract Cancer Biliary Tract Cancer	larotrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	gemcitabine + oxaliplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	gemcitabine + capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	cisplatin + gemcitabine Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Biliary Tract Cancer Biliary Tract Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Biliary Tract Cancer Biliary Tract Cancer	FOLFOX Sensitive: A2 - Guideline
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: B - Late Trials
HER-2 expression HER-2 expression	Biliary Tract Cancer Biliary Tract Cancer	ZW25 Sensitive: B - Late Trials
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials
HER-2 expression HER-2 expression	Cholangiocarcinoma Cholangiocarcinoma	trastuzumab + lapatinib Sensitive: B - Late Trials
RET fusion RET fusion	Cholangiocarcinoma Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Gallbladder Cancer Gallbladder Cancer	dostarlimab Resistant: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Cholangiocarcinoma Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Cholangiocarcinoma Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label
HER-2 overexpression HER-2 overexpression	Gallbladder Cancer Gallbladder Cancer	trastuzumab Sensitive: C1 - Off-label
FGFR3 mutation FGFR3 mutation	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Gallbladder Cancer Gallbladder Cancer	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Biliary Tract Cancer Biliary Tract Cancer	pembrolizumab Sensitive: C1 - Off-label
BRAF V600 BRAF V600	Cholangiocarcinoma Cholangiocarcinoma	vemurafenib Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Biliary Tract Cancer Biliary Tract Cancer	nivolumab + ipilimumab Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Cholangiocarcinoma Cholangiocarcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label
NTRK3 fusion NTRK3 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label
NTRK1 fusion NTRK1 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	Biliary Tract Cancer Biliary Tract Cancer	Herzuma (trastuzumab biosimilar) Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Biliary Tract Cancer Biliary Tract Cancer	trametinib Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Biliary Tract Cancer Biliary Tract Cancer	olaparib Sensitive: C1 - Off-label
ATM mutation ATM mutation	Biliary Tract Cancer Biliary Tract Cancer	olaparib Sensitive: C1 - Off-label
FGFR2 translocation FGFR2 translocation	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: C2 – Inclusion Criteria
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria
FGFR2 amplification FGFR2 amplification	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Biliary Tract Cancer Biliary Tract Cancer	gemcitabine Sensitive: C2 – Inclusion Criteria
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	dasatinib Sensitive: C2 – Inclusion Criteria
IDH1 R132C IDH1 R132C	Cholangiocarcinoma Cholangiocarcinoma	ivosidenib Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Biliary Tract Cancer Biliary Tract Cancer	M7824 Sensitive: C2 – Inclusion Criteria
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	metformin Sensitive: C2 – Inclusion Criteria
HER-2 overexpression HER-2 overexpression	Biliary Tract Cancer Biliary Tract Cancer	ZW25 Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Biliary Tract Cancer Biliary Tract Cancer	neratinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Gallbladder Cancer Gallbladder Cancer	crizotinib Sensitive: C3 – Early Trials
ERBB3 mutation ERBB3 mutation	Gallbladder Cancer Gallbladder Cancer	lapatinib Sensitive: C3 – Early Trials
HER-2 amplification HER-2 amplification	Gallbladder Cancer Gallbladder Cancer	trastuzumab Sensitive: C3 – Early Trials
HER-2 amplification HER-2 amplification	Gallbladder Cancer Gallbladder Cancer	lapatinib Sensitive: C3 – Early Trials
HER-2 amplification HER-2 amplification	Gallbladder Cancer Gallbladder Cancer	trastuzumab + lapatinib Sensitive: C3 – Early Trials
ATM mutation ATM mutation	Biliary Tract Cancer Biliary Tract Cancer	toripalimab Resistant: C3 – Early Trials
HER-2 amplification HER-2 amplification	Cholangiocarcinoma Cholangiocarcinoma	trastuzumab Sensitive: C3 – Early Trials
DDR DDR	Cholangiocarcinoma Cholangiocarcinoma	lenvatinib + toripalimab Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Cholangiocarcinoma Cholangiocarcinoma	lenvatinib + toripalimab Sensitive: C3 – Early Trials
ERBB3 mutation ERBB3 mutation	Gallbladder Cancer Gallbladder Cancer	trastuzumab Sensitive: C3 – Early Trials
ERBB3 amplification ERBB3 amplification	Gallbladder Cancer Gallbladder Cancer	trastuzumab Sensitive: C3 – Early Trials
ERBB3 amplification + ERBB3 mutation ERBB3 amplification + ERBB3 mutation	Gallbladder Cancer Gallbladder Cancer	trastuzumab Sensitive: C3 – Early Trials
HER-2 expression HER-2 expression	Biliary Tract Cancer Biliary Tract Cancer	ARX788 Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Cholangiocarcinoma Cholangiocarcinoma	Immunotherapy Sensitive: C3 – Early Trials
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Gallbladder Cancer Gallbladder Cancer	Debio 1347 Sensitive: C3 – Early Trials
BRAF L485W BRAF L485W	Gallbladder Cancer Gallbladder Cancer	BVD-523 Sensitive: C3 – Early Trials

Biliary Tract Cancer

Associations(234)

Associations
(234)